Granahan US Small Cap Discvs Fdrs USDAcc |
Performance History | 31/03/2024 |
Growth of 1,000 (EUR) |
Fund | 33.9 | 11.5 | -29.2 | 16.6 | 6.8 | |
+/-Cat | 17.0 | -15.2 | -11.7 | 3.5 | -2.2 | |
+/-Idx | - | -13.4 | -14.8 | 1.8 | -0.6 | |
Category: US Small-Cap Equity | ||||||
Benchmarks: Morningstar US Sml Ext NR USD |
Key Stats | ||
NAV 24/04/2024 | USD 15.88 | |
Day Change | 0.03% | |
Morningstar Category™ | US Small-Cap Equity | |
ISIN | IE00BZ3G1H34 | |
Fund Size (Mil) 24/04/2024 | USD 1.52 | |
Share Class Size (Mil) 24/04/2024 | USD 1.50 | |
Max Initial Charge | - | |
Ongoing Charge 01/01/2023 | 0.87% |
Investment Objective: Granahan US Small Cap Discvs Fdrs USDAcc |
The investment objective of the Fund is to seek capital appreciation through investment in small, dynamic and emerging growth companies. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Jeffrey Harrison 30/07/2021 | ||
Richard Watson 30/07/2021 | ||
Inception Date 30/06/2017 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
Russell 2000 Growth TR USD | Morningstar US Sml Ext NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Granahan US Small Cap Discvs Fdrs USDAcc | 29/02/2024 |
|
|
Top 5 Holdings | Sector | % |
Kiniksa Pharmaceuticals Ltd Class A | Healthcare | 3.27 |
CorVel Corp | Financial Services | 3.01 |
Zymeworks Inc Registered Shs | Healthcare | 2.93 |
Shockwave Medical Inc | Healthcare | 2.92 |
Syndax Pharmaceuticals Inc | Healthcare | 2.92 |
Increase Decrease New since last portfolio | ||
Granahan US Small Cap Discvs Fdrs USDAcc |